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Comprehensive population-wide analysis of Lynch
syndrome in Iceland reveals founder mutations
in MSH6 and PMS2
Sigurdis Haraldsdottir1,2,3, Thorunn Rafnar4, Wendy L. Frankel5, Sylvia Einarsdottir6,7, Asgeir Sigurdsson4,
Heather Hampel2, Petur Snaebjornsson8, Gisli Masson4, Daniel Weng2, Reynir Arngrimsson3,6, Birte Kehr4,
Ahmet Yilmaz2, Stefan Haraldsson6,9, Patrick Sulem4, Tryggvi Stefansson6, Peter G. Shields2,
Fridbjorn Sigurdsson6, Tanios Bekaii-Saab10, Pall H. Moller6, Margret Steinarsdottir6, Kristin Alexiusdottir11,
Megan Hitchins1, Colin C. Pritchard12, Albert de la Chapelle2, Jon G. Jonasson3,6,11, Richard M. Goldberg13,*
& Kari Stefansson3,4,*
Lynch syndrome, caused by germline mutations in the mismatch repair genes, is associated
with increased cancer risk. Here using a large whole-genome sequencing data bank, cancer
registry and colorectal tumour bank we determine the prevalence of Lynch syndrome,
associated cancer risks and pathogenicity of several variants in the Icelandic population.
We use colorectal cancer samples from 1,182 patients diagnosed between 2000–2009.
One-hundred and thirty-two (11.2%) tumours are mismatch repair deﬁcient per immuno-
histochemistry. Twenty-one (1.8%) have Lynch syndrome while 106 (9.0%) have somatic
hypermethylation or mutations in the mismatch repair genes. The population prevalence of
Lynch syndrome is 0.442%. We discover a translocation disrupting MLH1 and three muta-
tions in MSH6 and PMS2 that increase endometrial, colorectal, brain and ovarian cancer risk.
We ﬁnd thirteen mismatch repair variants of uncertain signiﬁcance that are not associated
with cancer risk. We ﬁnd that founder mutations in MSH6 and PMS2 prevail in Iceland unlike
most other populations.
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L
ynch syndrome (LS) is the most common inherited cause of
colorectal cancer (CRC). The estimated population fre-
quency is 1:370 to 1:2,000 in Western populations1,2. LS is
also associated with increased lifetime risk of several other cancer
types including endometrial and ovarian cancer3,4. LS prevalence
has never been determined across an entire nation.
Microsatellite instability (MSI) and mismatch repair deﬁciency
(dMMR) are hallmarks of LS-related CRC. About 15% of CRC
exhibit dMMR5 with 2–3% caused by germline mutations in the
MLH1, MSH2, MSH6, PMS2 or EPCAM genes6 while 12% of
CRC cases have somatic inactivation of MLH1 via promoter
hypermethylation (MLH1-hm)7. Furthermore, double somatic
mismatch repair (MMR) mutations may explain up to 67% of
dMMR CRC cases without LS or MLH1-hm8.
Several groups in Europe and the United States have
recommended universal screening of CRC9–12 using MSI
testing or immunohistochemistry for the MMR proteins to
identify potential LS cases. MLH1-hm can be assessed directly or
inferred by the presence of a somatic BRAF V600E mutation13.
Due to the low frequency of individual LS mutations and
heterogeneity in phenotypic expression, it has proven difﬁcult to
accurately establish population-based prevalences and to assess
the cancer penetrance of LS gene mutations. Furthermore,
numerous reported variants of uncertain clinical signiﬁcance
(VUS) complicate genetic counseling. Recently, a collaborative
effort was undertaken to reclassify MMR variants in the Interna-
tional Society for Gastrointestinal Hereditary Tumours (InSiGHT)
database (http://insight-group.org/variants/database/)14.
The Icelandic population offers several advantages for
studying the genetic epidemiology and associated cancer risks
of LS15. These include (i) a nationwide cancer registry dating
back to 1955; (ii) universal tumour banking since 1935;
(iii) documentation of the entire population’s genealogy over
centuries; and (iv) the isolation and relative homogeneity of the
population which enhances the potential to discover founder
mutations. To date, the DNA of over 150,000 Icelanders has
undergone whole-genome analysis on microarray platforms.
Additionally, 8,453 Icelanders have undergone whole-genome
sequencing (WGS). Using long-range phasing, these sequence
variants, down to a frequency ofo0.01%, have been imputed into
the genomes of those genotyped and into un-genotyped close
relatives identiﬁed via genealogic databases (familial imputation).
This familial imputation allows the inclusion of genotypes for
cancer cases that were diagnosed decades ago, greatly enhancing
the power of this study.
The objective of this study was to investigate the prevalence of
LS in the Icelandic population and to establish the different
etiologies for dMMR in a population-based CRC cohort.
Tumours from all CRC cases diagnosed from 2000–2009 were
screened for dMMR using immunohistochemistry and methyla-
tion assays and patients were genotyped for MMR variants
extracted from the deCODE database. Unexplained dMMR
cases underwent germline WGS and if still unexplained, tumour
ColoSeq. Furthermore, variants extracted from the deCODE
database were merged with the cancer registry to estimate the
cancer penetrance of LS gene mutations and cancer association of
VUS’s found in the Icelandic population. We ﬁnd that MSH6 and
PMS2 mutations prevail in the population with a LS prevalence of
1 in 226, the highest reported so far.
Results
LS founder mutations in the Icelandic population. Association
studies, using WGS data in the Icelandic population and infor-
mation on all cancer types, revealed three LS mutations that
showed signiﬁcant association with CRC and endometrial cancer
(Table 1). All three mutations are present at allelic frequencies
40.05%, presumably reﬂecting a founder effect in the population.
One mutation in MSH6 (p.Leu585Pro, class 3 per InSiGHT) and
another in PMS2 (p.Pro246Cysfs*3, class 5 per InSiGHT) were
found in 9 and 12 patients with dMMR CRC, respectively
(see below). A further mutation in PMS2 (p.Met1?; pathogenic
mutation in National Center for Biotechnology Information
(NCBI) ClinVar16) was identiﬁed in the population but not in any
CRC patients diagnosed during 2000–2009. These mutations were
imputed and the prevalence of LS in the Icelandic population
determined to be 0.442% or one in 226 individuals. The
imputation quality was tested by direct genotyping of the three
variants. The concordance between imputed and directly
measured genotypes was 1.00 for PMS2 p.Pro246Cysfs*3 and
PMS2 p.Met1? and 0.99 for MSH6 p.Leu585Pro (Supplementary
Table 1).
Patient characteristics. A total of 1,208 patients were diagnosed
with colorectal carcinoma in Iceland from 2000–2009, with 1,182
(97.8%) included in this study. Patient characteristics are shown
in Table 2. All patients with abnormal immunohistochemistry
and 78.2% of patients with normal immunohistochemistry had
germline DNA available for genotyping (80.6% of the cohort).
Table 1 | Lynch syndrome mutations in the Icelandic population.
Gene Hg38 location Coding change Protein change Pathogenicity* Nr. pts in CRC cohort Carrier frequency
PMS2 chr7:5997387 c.736_741del6ins11 p.Pro246Cysfs*3 Class 5 12 0.234%w
PMS2 chr7:6009018 c.2T4A p.Met1? Pathogenicz 0 0.092%w
MSH6 chr2:47799737 c.1754T4C p.Leu585Pro Class 3 9 0.080%w
MLH1 chr3:36998760 Balanced translocation
(Fig. 1)
NK 1 1 Familyy
MSH6 chr2:47798826 c.843_844insAC p.Val282Thrfs*10 NK 1 1 Familyy
MSH6 chr2:47803500 c.3261dupC p.Phe1088Leufs*5 Class 5 1 1 Familyy
MSH6 chr2:47804984 c.3514dupA p.Arg1172Lysfs*5 Class 5 1 1 Familyy
MSH2 chr2:47478506 c.2445T4A p.Tyr815* NK 0 1 Familyw
PMS2 chr7:6004007 c.211_214del p.Asn71Aspfs*4 NK 1 1 Patienty
PMS2 chr7:5982885 c.2113G4A p.Glu705Lys Class 3 1 1 Patienty
CRC, colorectal cancer; MMR, mismatch repair; NK, not known; Nr., number; pts¼ patients.
*Pathogenicity as listed in InSiGHT, if known.
wExtracted from deCODE’s database.
zListed as pathogenic in NCBI ClinVar16, not listed in InSiGHT.
yFound by sequencing patients with dMMR CRC.
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LS and dMMR in the CRC cohort. MMR immunohistochem-
istry was abnormal in 132 patients (11.2%; Table 3). MLH1-hm
was found in 90 cases (7.6% of the cohort). Twenty-one patients
with abnormal immunohistochemistry and six patients with
normal immunohistochemistry had LS mutations (Table 1
and Supplementary Table 2). Eight different LS mutations
were identiﬁed, including the MSH6 p.Leu585Pro and PMS2
p.Pro246Cysfs*3 mutations described above, four private muta-
tions (found in a single family each) and two mutations in PMS2,
not found in other family members or the population (de novo or
very recent). The prevalence of LS in the CRC cohort was
therefore 2.3% (27/1182). The median age at CRC diagnosis of
patients with theMSH6 p.Leu585Pro mutation was 60 (Q1 51, Q3
73; range 41–75) and the median age of patients with the PMS2
p.Pro246Cysfs*3 mutation was 60.5 (Q1 50.5, Q3 70; range
31–86). One patient with PMS2 tumour loss had a class 3 PMS2
variant (p.Glu705Lys). Tumour ColoSeq identiﬁed the same
variant as well as likely loss of heterozygosity (LOH) in the
tumour (Table 4). We, therefore, believe this variant is pathogenic
and classiﬁed this case as having LS. Tumour ColoSeq was per-
formed on 5 of 6 tumour samples from patients with LS who had
normal MMR IHC (Table 4). Second hits were found in 3 cases
with a MSH6 p.Leu585Pro mutation but not 2 cases with a PMS2
p.Pro246Cysfs*3 mutation. Twenty-one patients with dMMR
tumours had neither a LS mutation or MLH1-hm. Sixteen
patients were found to have double somatic MMR mutations by
ColoSeq tumour testing (1.4% of the cohort; Table 4). Five
dMMR cases remained unexplained, three cases had one somatic
MSH2 mutation and tested negative for MSH2 methylation sug-
gesting an unidentiﬁable MSH2 mutation in germline or tumour
DNA. Two cases failed tumour testing due to low tumour DNA
content. None of these patients had a convincing family history of
cancer. By using the 953 individuals (80.6% of the cohort) that
had germline genotyping as a denominator, the sensitivity and
speciﬁcity of IHC in detecting LS was 77.8% and 97.7%, respec-
tively. The positive and negative predictive value of abnormal
IHC predicting LS was 50.0% and 99.3%, respectively.
Origin of LS mutations. The PMS2 p.Pro246Cysfs*3 mutation
carriers in Iceland, share a short haplotype with individuals
from Sweden, Britain and the US (Supplementary Table 3),
indicating that this mutation arose from a common ancestor,
previously dated back 1,625 years17. Three private LS mutations
in the CRC cohort and one private mutation outside of the
CRC cohort were identiﬁed (Table 1 and Supplementary Fig. 1).
Table 2 | Patient and tumour characteristics in the colorectal cancer cohort.
Proﬁcient MMR
(n¼ 1,044)
Lynch syndrome
(n¼ 27)*
MLH1-hm
(n¼90)
Double somatic MMR
(n¼ 16)
dMMR unexplained
(n¼ 5)
Age, median (Q1, Q3) 71 (61, 78) 62 (55, 72) 78 (73, 84) 69 (57, 79) 75 (35, 86)
Gender
Male 601 (57.6%) 22 (81.5%) 25 (27.8%) 9 (56.3%) 2 (40.0%)
Female 443 (42.4%) 5 (18.5%) 65 (72.2%) 7 (43.7%) 3 (60.0%)
Stage at diagnosis
I 193 (18.5%) 5 (18.5%) 9 (10.0%) 1 (6.3%) 3 (60.0%)
II 282 (27.0%) 16 (59.3%) 47 (52.2%) 9 (56.3%) 2 (40.0%)
III 298 (28.5%) 4 (14.8%) 24 (26.7%) 4 (25.0%) 0
IV 230 (22.0%) 2 (7.4%) 6 (6.7%) 1 (6.3%) 0
Unknown 41 (3.9%) 0 4 (4.4%) 1 (6.3%) 0
Location
Right 357 (34.7%) 14 (51.9%) 76 (86.4%) 13 (81.3%) 2 (40.0%)
Left 366 (35.5%) 9 (33.3%) 8 (9.1%) 2 (12.5%) 1 (20.0%)
Rectumw 307 (29.8%) 4 (14.8%) 4 (4.5%) 1 (6.2%) 2 (40.0%)
Metachronous 30 (2.9%) 1 (3.7%) 6 (6.7%) 0 0
Synchronous 30 (2.9%) 2 (7.4%) 4 (4.4%) 0 0
dMMR, deﬁcient mismatch repair activity; IHC, immunohistochemistry; MLH1-hm, MLH1 hypermethylation; MMR, mismatch repair; N, number; Q, quartiles.
*Six LS patients with CRC with normal IHC are included here.
wRectosigmoid location is included with rectum.
Table 3 | Colorectal cancer cases with abnormal mismatch repair protein immunohistochemistry.
Absent stains on IHC Etiology of mismatch repair deﬁciency
MLH1-hm LS Double somatic MMR Unexplained Nr. cases
MLH1/PMS2 90* 1 8 1 100 (8.5%)
MSH2/MSH6 NA 2w 5 4 11 (0.9%)
MSH6 NA 7 1 0 8 (0.7%)
PMS2 NA 11z 2 0 13 (1.1%)
Total 90 (7.6%)y 21 (1.8%) 16 (1.4%) 5 (0.4%) 132 (11.2%)
IHC, immunohistochemistry; LS, Lynch syndrome; MLH1-hm, MLH1 hypermethylation; NA, not applicable; Nr., number.
The denominator in the table is all CRC patients (n¼ 1182). The six patients with LS and normal IHC are not depicted in this table.
*One case had MLH1/PMS2/MSH2 missing.
wOne case had MSH2/MSH6/PMS2 missing.
zOne case had MSH6/PMS2 missing.
yThree biopsy cases failed MLH1-hm testing but were positive for BRAF V600E via IHC.
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The MSH6 mutations (p.Val282Thrfs*10, p.Phe1088Leufs*5,
p.Arg1172Lysfs*5) and the MSH2 mutation (p.Tyr815*) were
traced back to ancestors in the 1700–1800s by genotyping
individuals who shared haplotypes around the mutation.
Interestingly, a novel balanced translocation, T(3p22;5q31), with
breakpoints in MLH1 intron 3 and ZCCHC10, was identiﬁed by
WGS and conﬁrmed by karyotyping and ﬂuorescence in situ
hybridization (FISH) in a family with high incidence of cancer
(Fig. 1). This translocation was found in a parent and was
inherited by several offspring with nearly 100% cancer penetrance
(colorectal, endometrial, gastric, ovarian and renal cell carcinoma;
three offspring developed two cancers) but not found in the 8,453
Icelanders who have undergone WGS.
LS and associated cancer risks. The three imputed mutations
(MSH6 p.Leu585Pro, PMS2 p.Pro246Cysfs*3 and PMS2 p.Met1?)
vary in risk for different LS-associated cancer types as shown in
Table 5. The MSH6 p.Leu585Pro mutation is associated with a
Table 4 | Somatic mismatch repair gene mutations as tested by ColoSeq.
Study
ID
mSINGS MSI MLH1-hm Absent stains on
IHC
Gene MMR mutation no.1 MMR mutation no. 2 Outcome
197 0.4062 MSI-H 10% MLH1/PMS2 MLH1 c.493del (p.A165Lfs*2) LOH Double somatic
237 0.4531 MSI-H 4% MLH1/PMS2 MLH1 c.2237del (p.L746Rfs*37) LOH Double somatic
466 0.5538 MSI-H 5% MLH1/PMS2 MLH1 c.1684C4T (p.Q562*) LOH Double somatic
506 0.5079 MSI-H 4% MLH1/PMS2 MLH1 c.199G4A (p.G67R) LOH Double somatic
745 0.4923 MSI-H 10% MLH1/PMS2 MLH1 c.1783_1784del
(p.S595Wfs*14)
LOH Double somatic
985 0.4462 MSI-H 10% MLH1/PMS2 MLH1 c.588del (p.K196Nfs*6) c.171del; c.299G4A
(p.K57Nfs*2; p.R100Q)
Double somatic
1034 0.5538 MSI-H 6% MLH1/PMS2 MLH1 c.2142G4A (p.W714*) c.670_673dup (p.R226*) Double somatic
1141 0.4923 MSI-H NT MLH1/PMS2 MLH1 c.2206G4T (p.E736*) LOH Double somatic
246 0.4769 MSI-H NT MSH2/MSH6 MSH2 c.545_552del
(p.D182Vfs*4)
c.1661þ 1G4A (Splicing) Double somatic
1082 0.3492 MSI-H NT MSH2/MSH6 MSH2 c.82del (p.E28Rfs*36) c.1310del (p.V437Gfs*17) Double somatic
1049 0.4754 MSI-H NT MSH2/MSH6 MSH2 c.942þ 3A4T (splicing) LOH Double somatic
959 0.5846 MSI-H NT MSH2/MSH6 MSH2 c.2459-2A4C (splicing) c.2352del (p.H785Mfs*27) Double somatic
951 0.5156 MSI-H NT MSH2/MSH6 MSH2 c.425C4G (p.S142*) c.942þ 3A4T (splicing) Double somatic
509 0.1587 MSS NT MSH6 MSH2 Inversion; c.2210þ 7G4T
(germline)*
LOH (maybe) Possibly double
somatic
1231 0.4462 MSI-H NT PMS2 PMS2 c.325delG (p.E109Kfs*3) c.444delC; c.903þ 1G4A
(p.Y149Tfs*52; splicing)
Double somatic
1022 0.2857 MSI-H NT PMS2 PMS2 Exon 11 homozygous
deletion
LOH Double somatic
427 0.4462 MSI-H NT PMS2 PMS2 c.2113G4A (p.E705K,
germline)
LOH (likely) Lynch syndromew
1057 0.5692 MSI-H NT PMS2 PMS2 c.211_214del (p.N71Dfs*4,
germline)
c.2113G4A (p.E705K), LOH
(maybe)
Lynch syndromew
339 0.5626 MSI-H 5% MLH1/PMS2 MLH1 Germline translocationz c.2041G4A (p.Ala681Thr) Lynch syndromew
786 0.2787 MSI-H NT Normal (MSH6
weak, 1–5%)
MSH6 c.1754T4C (p.L585P,
germline)
c.3509delT (p.I1170Mfs*14) Lynch syndromew
30 0.1228 MSS NT Normal (MSH6
weak, 5%)
MSH6 c.1754T4C (p.L585P,
germline)
c.3261del (p.F1088Serfs*2) Lynch syndromew
94 0.4032 MSI-H NT Normal (MSH6
weak, 20–30%)
MSH6 c.1754T4C (p.L585P,
germline)
c.3016T4G (p.Y1006D) Lynch syndromew
1250 0.1538 MSS NT Normal PMS2 c.736_741del6ins11
(p.Pro246Cysfs*3,
germline)
None detected Lynch syndrome
(sporadic tumour)w
873 0.0615 MSS NT Normal PMS2 c.736_741del6ins11
(p.Pro246Cysfs*3,
germline)
None detected Lynch syndrome
(sporadic tumour)w
162 0.5385 MSI-H NT MSH2/MSH6 MSH2 c.2458þ 2delT (splicing) None detectedy Not solved
1127 0.2188 MSI-H NT MSH2/MSH6 MSH2 c.943-1G4C (splicing) None detectedy Not solved
1108 0.4154 MSI-H NT MSH2/MSH6 MSH2 c.2131C4T (p.R711*) c.2635-10T4G (germline,
splicing)||,y
Not solved
418 0.1077 MSS NT MSH2/MSH6 MSH2 c.1077-2736T4G (deep
intronic)
LOH Not solvedz
827 0.0923 MSS 2% MLH1/PMS2 None Failed testing Not solvedz
240 0.2742 MSI-H 14% MLH1/PMS2 None No hits to MMR
genes—BRAF V600E
MLH1-hm
LOH, loss of heterozygosity; MLH1-hm, MLH1 hypermethylation; MMR, mismatch repair; MSI-H, microsatellite unstable high; mSINGS, microsatellite instability by next-generation sequencing; MSS,
microsatellite stable, NT ,not tested.
*c.2210þ 7G4T (rs374675118)—minor allelic frequency is 0.969% in the Icelandic population without CRC association (see Table 6: VUS).
wTwo cases with de novo germline PMS2 mutations (427, 1057) and the MLH1 germline translocation (339) and ﬁve cases with normal MMR IHC underwent tumour Coloseq testing to conﬁrm a
second hit.
zSee Fig. 1.
yNegative for MSH2 hypermethylation.
||Not clearly pathogenic.
zIndeterminate study due to low tumour content.
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Figure 1 | Novel MLH1 translocation. (a) The top half of the ﬁgure displays enlarged GRCh38 reference sequences from within MLH1 on chromosome 3
(blue) and from the reverse complement of chromosome 5 within ZCCHC10 (red) in a patient with CRC with MLH1/PMS2 absent on IHC. The bottom
shows the translocation breakpoints observed in the sequencing data. The translocation connects an intron of MLH1 with an intron of ZCCHC10 in sense of
the genes’ orientations. At the breakpoint, a 3-bp duplication is present on both translocation haplotypes (dark blue), a 5-bp deletion is missing from both
translocation haplotypes (dark red), and a 10-bp motif from nearby got inserted in reverse complemented orientation into one of the translocation
haplotypes (yellow). (b) FISH, chromosome 3 (red CY3), chromosome 5 (green ﬁtc). Chromosomes 3 and 5 are marked with white arrows. The scale
shown is 5mm. (c) Family tree with cancers and age at diagnosis. Proband is indicated with an arrow.
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nearly 50% lifetime risk of endometrial cancer and a 36% and
25% risk of CRC in males and females as well as aB12% lifetime
risk of brain cancer (glioma). The two PMS2 mutations are
associated with a signiﬁcantly increased risk of endometrial,
colorectal and ovarian cancer, although the overall cancer risks
are lower than for the MSH6 mutation. Risks for other cancers
were not signiﬁcantly increased and are shown in Supplementary
Table 4.
Variants of uncertain signiﬁcance. We identiﬁed 13 MMR gene
variants previously described as VUS’s and ten novel variants, in
the Icelandic population. These were imputed and odds ratios for
CRC estimated. None of these variants were associated with
cancer risk or unexplained dMMR suggesting they are benign
variants. These variants are listed in Table 6.
Discussion
In this comprehensive nationwide study, WGS and imputation
were combined with dMMR screening of CRC to accurately
determine the prevalence of LS in the Icelandic population. LS
causes 2.3% of all CRC in Iceland which is similar to the
prevalence in two CRC population-based studies from Finland19
and the US6 but it is higher than LS prevalence in Southern
Europe20–23. The distribution of mutations among the MMR
genes in Iceland is unique. LS is predominantly caused by
mutations in MSH6 and PMS2 which are responsible for 96% of
all LS cases in the CRC cohort while mutations in these two genes
cause 28% of LS-associated CRC in the US6. Only a single
mutation in MSH2 and a single novel MLH1 translocation were
found in the population.
The low rates of MLH1 and MSH2 mutations constitute a
negative founder effect, that is, the founders may not have
introduced MLH1 and MSH2 mutations into the population.
Genetic drift, which is more common in smaller populations, may
also have inﬂuenced low rates of MLH1 and MSH2 mutations.
Furthermore, the higher cancer penetrance and earlier onset
associated with MLH1 and MSH2 mutations may have impacted
reproductive ﬁtness. Over 50 mutations showing founder effects
have been described across the world and in some populations
they have a large effect on the LS gene distribution24. In Finland,
two MLH1 mutations cause 450% of all LS cases19,25 and in
the Netherlands26 and Sweden27, MSH6 mutations are unusually
highly prevalent. The PMS2 p.Pro246Cysfs*3 mutation in Iceland
shares a haplotype with cohorts from Sweden, US and Britain17.
This mutation was previously dated back to around 1,625 years
ago17, a time before Iceland was settled and it is likely to have
entered the gene pool via one of the original settlers. The MSH6
p.Leu585Pro and PMS2 p.Met1? mutations have been described
in InSiGHT and NCBI ClinVar but are not known to be founder
mutations in any population. The MSH6 p.Leu585Pro mutation
is clearly pathogenic in this study with a strong cancer risk
association. The PMS2 p.Met1? mutation has a cancer risk
association indicating that it is a pathogenic mutation. In
addition, four private LS mutations were found and traced back
to a single common ancestor in each family who lived in the
1700–1800s.
The MLH1 germline translocation described is to our knowl-
edge the ﬁrst case of a translocation causing LS. The translocation
is passed to offspring and affected family members had close to
100% cancer penetrance. Screening for translocations where LS is
suspected and germline mutations cannot be found should be
considered.
The population-based prevalence of LS has been estimated in
CRC and endometrial cancer studies in several countries but no
country has determined the prevalence empirically. It has been
postulated that LS prevalence is higher than estimated in most
studies1 and here we show the highest prevalence so far of 0.442%
or 1:226 individuals. Of note, the prevalence is higher than
elsewhere even though the proportion of LS in CRC is just 2.3%.
This is due to the markedly low cancer penetrance of the MSH6
and PMS2 mutations in Iceland as compared with cancer
penetrance with MLH1 and MSH2 mutations, dominating in
most populations.
One of the strengths of this study is the ability to determine
cancer risk for each of the imputable mutations. This will help
tailor genetic counseling in Iceland, speciﬁc to the individual
Table 5 | Icelandic Lynch syndrome mutations and odds ratios for different cancers.
Cancer type Odds
ratio
95% Conﬁdence
interval
P-value Cases Controls Info Cancer
risk (M)
Cancer
risk (F)
MSH6 p.Leu585Pro
Pop carrier freq: 0.080%
Endometrial cancer 32.8 13.5–80.0 1.61 10 14 923 115,104 0.92 NA 49.2%
Colorectal cancer 10.1 5.1–20.1 4.19 10 11 3834 262,425 — 36.4% 25.3%
Colon cancer 7.5 3.3–17.0 1.89 106 2793 263,466 — 17.9% 12.7%
Rectal cancer 12.4 4.4–34.8 1.79 106 1082 260,587 — 16.1% 9.9%
Brain cancer (glioma) 8.9 2.2–36.2 2.19 10 3 702 358,789 — 13.4% 10.7%
PMS2 p.Pro246Cysfs*3
Pop carrier freq: 0.234%
Endometrial cancer 9.9 4.9–19.8 1.30 10 10 923 115,104 0.99 NA 14.8%
Colorectal cancer 3.6 2.2–5.9 7.64 10 7 3834 262,425 — 12.9% 9.0%
Colon cancer 3.8 2.2–6.6 1.7 10 7 2793 263,466 — 9.2% 6.5%
Rectal cancer 2.3 0.8–6.9 1.2 10 1 1082 260,587 — 3.0% 1.9%
Ovarian cancer 3.9 1.3–11.9 1.53 10 2 779 121,299 — NA 3.5%
PMS2 p.Met1?
Pop carrier freq: 0.092%
Endometrial cancer 7.5 2.4–23.5 5.53 104 923 115,104 0.99 NA 11.3%
Colorectal cancer 2.2 0.94–5.3 7.01 10 2 3834 262,425 — 8.0% 5.5%
Colon cancer 2.7 1.1–6.8 3.7 10 2 2793 263,466 — 6.4% 4.6%
Rectal cancer 0.9 0.13–6.7 5.4 10 1 1082 260,587 — 1.2% 0.8%
Ovarian cancer 6.6 1.8–24.3 4.16 10 3 779 121,299 — NA 6.0%
F, females; Pop carrier freq, population-based carrier frequency; LS, Lynch syndrome; M, males; NA, not applicable.
Cancer risks are calculated by using lifetime cancer risk at age 75 obtained from the Icelandic Cancer Registry18.
In total 16 cancers were tested for each of the mutations. Signiﬁcant P-valueo3.13 10 3 to correct for multiple tests. Info represents the imputation quality of the variant. P-values were obtained by
logistic regression analysis.
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mutation. The MSH6 p.Leu585Pro mutation is associated with a
high (B50%) lifetime risk of endometrial cancer while the PMS2
mutations (p.Pro246Cysfs*3 and p.Met1?) have a lower lifetime
risk of cancer. One of the limitations of this study is the small size
of the population, which makes it difﬁcult to estimate the risk of
rare cancers such as brain cancer (conﬁdence intervals around
odds ratios are wide).
Our two-pronged approach, of linking population-based MMR
variants to a dMMR CRC phenotype, imputing these variants
into the population and performing an association analysis with
the cancer registry, strengthens the assumption of pathogenicity
(or lack thereof). The MSH6 p.Leu585Pro mutation is described
as a class 3 VUS in InSiGHT but, based on our data, should be
reclassiﬁed as a pathogenic mutation. Thirteen other VUS’s were
not associated with a dMMR phenotype or increased cancer risks.
Some of these variants can be reclassiﬁed as benign variants based
on our data (variants with high population frequency and low
odds ratios with narrow 95% conﬁdence interval while others
may require additional data before reclassiﬁcation).
The incidence of dMMR via immunohistochemistry (11.2%)
was lower than reported in many studies. In this study, an
etiology was found for nearly all dMMR cases, leaving very few
unexplained dMMR cases (only 0.4% of all cases remained
unexplained). As 80% of all cases were genotyped, sensitivity and
speciﬁcity could be calculated for the immunohistochemistry
method. In three cases with the MSH6 p.Leu585Pro germline
mutation, the stains were weak but present in 41% of cells
(Supplementary Table 2) and a second tumour mutation was
found on ColoSeq (Table 4) indicating that these tumours
developed as a result of LS. In two PMS2 p.Pro246Cysfs*3 cases
with strong stains ColoSeq did not detect a second tumour
mutation so these patients developed a sporadic CRC unrelated to
their germline mutation. Sporadic tumour development is likely
more common with the lower penetrance mutations in MSH6
and PMS2.
The population-based incidence of double somatic MMR
mutations in CRC is described in this study for the ﬁrst time. In
total, 1.4% of all CRC had double somatic MMR mutations. These
cases followed the more traditional pattern of MMR mutations
with 81.3% of the mutations occurring in MLH1 and MSH2. The
cancer etiology in three cases with just one somatic hit in MSH2
remains unclear. The family history was unconvincing so it is
unlikely that a LS mutation was missed. Nevertheless such cases
present a challenge for genetic counseling. The tumour location
Table 6 | Mismatch repair gene variants of uncertain signiﬁcance and associated colorectal cancer risk in the Icelandic
population.
Gene Hg38
location
IHC stains in CRC
pts with variant*
Protein change InSiGHT
classiﬁcation
Carrier frequency
(%) in controls
Odds ratio
for CRC
95%
Conﬁdence
interval
P-value Info
MLH1
chr3:36993584 Normal (1) p.Glu13Lys Class 3 0.06 0.94 0.22–4.12 0.94 0.96
chr3:36993612 MLH1-hm (1) p.Gly22Ala Class 3 0.07 0.78 0.33–1.88 0.58 0.99
chr3:37017517 Normal (2) p.Glu268Gln NK 0.08 1.60 0.51–5.07 0.42 0.95
chr3:37017536 None p.Lys274Arg NK 0.22 0.78 0.33–1.88 0.58 0.91
MSH2
chr2:47429940 Normal (4) p.Glu425.¼ Class 3w 0.26 0.62 0.26–1.45 0.27 0.99
chr2:47445555 Normal (1) p.His428Gln NK 0.07 1.85 0.65–5.25 0.25 1.00
chr2:47476525 Normal (7), MLH1-hm (1) p.Val722Ile Class 3w 0.74 0.79 0.48–1.30 0.36 0.98
chr2:47476578 Normal (15), MLH1-hm (1),
MSH6 miss (1)z
c.2210þ 7G4T
Splicing
NK 1.94 0.68 0.50–0.93 0.02 0.99
MSH6
chr2:47783306 Normal (5) p.Ala25Ser Class 3 0.51 1.04 0.61–1.76 0.89 0.96
chr2:47796058 Normal (5) MLH1-hm (1) p.Met208Val Class 3 0.50 1.39 0.87–2.23 0.17 0.98
chr2:47801021 Normal (2) p.Lys1013Thr VUS on
NCBIw
0.55 0.72 0.42–1.22 0.22 1.00
chr2:47803464 Normal (3) p.Pro1073Ser Class 3 0.1 1.36 0.47–3.93 0.57 1.00
chr2:47803506 Normal (14) MLH1-hm (2)
MLH1 miss (1)y
p.Pro1087Ser Class 3w 1.21 0.85 0.59–1.22 0.38 1.00
chr2:47806495 Normal (3) p.Ile1283dup NK 0.34 1.13 0.61–2.09 0.69 1.00
PMS2
chr7:6009009 Normal (1) MLH1-hm (1) p.Ala4Gly NK 0.04 2.64 0.62–11.2 0.19 0.98
chr7:6006003 Normal (17) MLH1-hm (1)
PMS2 fs (1)
p.Ile18Val Class 3w 1.73 0.90 0.67–1.21 0.47 0.99
chr7:6002515 None p.Val159Met Class 3 0.05 0.96 0.15–6.31 0.96 0.96
chr7:5995539 None p.Ala300Pro NK 0.03 0.02 0.00–8.04 0.19 0.98
chr7:5989940 Normal (1) p.Asn335Ile VUS on NCBI 0.03 1.38 0.24–7.97 0.72 0.93
chr7:5987328 Normal (5) MLH1-hm (1) p.His479Gln Class 3 0.30 1.12 0.58–2.15 0.75 0.98
chr7:5987315 None p.Pro484Thr NK 0.04 0.02 0.00–4.18 0.15 0.95
chr7:5987213 Normal (6) MLH1-hm (1) p.Glu518Lys NK 0.33 1.62 0.95–2.77 0.08 0.99
chr7:5986784 Normal (3) p.Glu661Lys NK 0.29 1.04 0.52–2.06 0.92 0.97
CRC, colorectal cancer; fs, frameshift; IHC, immunohistochemistry; miss, missing on stains; MLH1-hm ,MLH1-hypermethylated; NCBI, NK¼ not known; pts, patients; seq, sequenced; VUS, variants of
unknown signiﬁcance. Info represents the imputation quality of the variant. P-values were obtained by logistic regression analysis.
*This column displays patients in the CRC cohort with the variant (either by sequencing or imputation) and their tumour MMR stain (# patients in parenthesis).
wThese variants can be reclassiﬁed as benign variants based on the population frequency and low odds ratio for CRC.
zPatient #509 with MSH6 absent on MMR tumour immunohistochemistry with possible double somatic hit (see Table 4).
yPatient #506 with MLH1/PMS2 absent on MMR tumour immunohistochemistry with double somatic hit (see Table 4).
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in LS patients was left-sided or rectal in B50% of cases while it
was predominantly right-sided in the MLH1-hm and double
somatic MMR cases (480%). It is possible that left-sidedness is
more common with MSH6 and PMS2 mutations as compared
with MLH1 and MSH2 mutations. Less than 10% of patients with
dMMR CRC presented with metastastic disease, similar to other
studies on dMMR CRC. A male predominance was seen in the LS
group, a female predominance in the MLH1-hm group while the
double hit sporadic tumours had a more even gender distribution.
In conclusion, this study has mapped the prevalence of LS in
the Icelandic population, and its associated cancer risks and
established that one in 226 Icelanders carry this syndrome.
Furthermore, the contribution of different etiologies to dMMR
CRC has been described. It is likely that among the population of
320,000 Icelanders, 41,000 individuals carry mutations causing
LS. Identifying these individuals and establishing a cancer
screening program are imperative next steps. Thirteen class 3
variants were not associated with an increased cancer risk and
one class 3 variant was determined to be pathogenic; these results
could guide counseling of patients with these variants. Finally, we
have shown that a combined approach of phenotypic screening
and population-based WGS can be used to extensively map out
an inherited syndrome with a well-recognized phenotype.
Methods
CRC patient population. All patients diagnosed with CRC in Iceland from 1
January 2000 to 31 December 2009 as identiﬁed through the Icelandic Cancer
Registry (http://www.krabbameinsskra.is) were included in the study. Figure 2
depicts the study design and reasons for exclusion. The Icelandic National
Bioethics Committee (VSNb2013010033/03.15), the Icelandic Data Protection
Authority (2013010109TS), and the Ohio State University (OSU) Institutional
Review Board (2013C0144) approved this study. Descriptive statistics (median with
quartiles for age and frequency for categorical variables) were provided to sum-
marize the patient population. Cases where the origin of the primary tumour was
regarded to be non-colonic (appendix, ileum and so on.) or unknown were
excluded. Charts were accessed and clinical information obtained. Foreigners and
patients without available tumour material were excluded. In cases of synchronous
CRC, only the tumour with the most advanced stage or stage subdivision was
analysed. In cases of metachronous CRC, the tumour diagnosed in the deﬁned
period was used (the ﬁrst one if there were two).
Immunohistochemistry and MLH1 hypermethylation testing. Haematoxylin
and eosin stained tumour slides (obtained from Landspitali University Hospital,
Akureyri Hospital and Histopathology Institute, Sudurlandsbraut) were reviewed
and formalin-ﬁxed parafﬁn embedded tissue blocks selected for further analysis.
Tissue microarrays were built at the OSU Pathology Core Facility with two 1.0mm
cores from each case. Immunoperoxidase staining was performed using primary
antibodies for MLH1 (Novacastra, Buffalo Grove, IL; NCL-L-MLH-1; Clone:ESO5;
diluted 1:500), MSH2 (Calbiochem, [Merck Biosciences AG], Basel-Land, Swit-
zerland; NA-27; Clone:FE11; diluted 1:3,000), MSH6 (Epitomics Inc, Burlingame,
CA; AC-0047; Clone:EP49; diluted 1:800) and PMS2 (BD Pharmingen, San Jose,
CA; 556415; clone:A16-4; diluted 1:300). Stains were scored as present with con-
vincing nuclear staining in tumour cells with a positive internal control. In cases
where only biopsies were available or rectal cancer cases where pre-radiation
therapy biopsy samples were chosen, biopsies were stained for MSH6 and PMS2.
If either were lost, stains were performed for MLH1 (if PMS2 lost) and MSH2
(if MSH6 lost). In cases scored as absent where noMLH1-hm or germline mutation
was found, stains were repeated on a whole section (if previously done on tissue
microarrays). In cases found to have LS with normal immunohistochemistry, stains
were repeated on a whole section.
Tumours with MLH1 loss were tested for MLH1-hm by pyrosequencing using
the Pyromark Q96 CpG MLH1 kit (QIAGEN, Hilden, Germany). Up to ﬁve
1.0mm cores were used for tumour DNA and germline DNA extraction by
standard methods. Methylation levels of Z15% were classiﬁed as positive for
hypermethylation. The Pyromark Q96 CpG MLH1 kit (QIAGEN, Hilden,
Germany) tests hypermethylation in four sites of the promoter region of MLH1,
positions  209 to  188. Polymerase chain reaction is used to amplify the region
and the degree of methylation of four CpG sites is analysed in a single
pyrosequencing reaction by taking the average of four sites. In cases where only
biopsy tissue was available and MLH1-hm testing failed, BRAF immunohisto-
chemistry for the V600E mutation was performed as previously described using the
VE1 antibody (1:700, incubation 15min; Spring Bioscience, Pleasanton, CA) with
an automated staining system (Bond Autostainer; Leica Microsystems, Buffalo
Grove, IL)28. BRAF V600E immunohistochemistry was graded as positive for the
mutation when diffuse cytoplasmic staining in tumour cells was seen.
Detection of LS mutations. The whole genomes of 8,453 Icelanders, irrespective
of cancer status, were sequenced using Illumina technology to a mean depth of at
All patients (n=1,208) with
CRC 2000–2009 in Iceland
Blood genotyping for
known MMR variants 
and MLH1-hm CRC
testing
1,182 patients
included (97.8%)
No further testing (n=229)
All MMR proteins
present (n=1,050)
Blood genotyping for known
MMR variants (n=821)
LS
(n=6)
LS (n=15)
LS (n=6)
Blood WGS (n=27)
Tumour ColoSeq (n=21)
Double somatic (n=16) 1 hit to MSH2 (n=3) MSH2 hypermethylation testing
Normal
(n=815)
IHC for MLH1, MSH2,MSH6 and PMS2 on all
(MSH6 and PMS2 for biopsies (n=270) with
reflexive partner testing* if abnormal)
MLH1/PMS2 absent (n=100)
MLH1-hypermethylation
positive CRC (n=90)
MSH2/MSH6,MSH6 or
PMS2 absent (n=32)
All MMR variants in the
population extracted
from deCODE's genetic
database 
Patients excluded (2.2%) for:
11Insufficent material
8 Unknown primary
3 Material not found
4 Foreigners 
21.8% without available blood
78.2% without available blood
*Reflexive partner testing
was done for biopsies,i.e if
MSH6 was abnormal, MSH2
IHC was added; if PMS2 was
abnormal, MLH1 IHC was
added
Negative
Negative
If methy
lation ne
gative
or borde
rline (n=1
0)
Blood genotyping for
known MMR variants
Figure 2 | Study design. CRC, colorectal cancer; IHC, immunohistochemistry; LS, Lynch syndrome; WGS, whole-genome sequencing.
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least 10 , unveiling 31.6 million single-nucleotide polymorphisms (SNP) and
short insertions/deletions that meet stringent quality criteria. These variants were
imputed into 150,656 Icelanders whose DNA had been genotyped with various
Illumina SNP chips and phased using long-range phasing29–30.
All patients with dMMR tumours had germline DNA genotyped for MMR
variants found by WGS of the 8,435 Icelanders. If no LS mutations were identiﬁed,
WGS was undertaken on blood samples with Illumina technology or, in cases
where blood DNA was not available, DNA from archived formalin-ﬁxed parafﬁn
embedded normal tissue was subjected to Sanger sequencing of the MMR genes.
Single variant genotyping was carried out by Sanger sequencing. The PMS2
p.Pro246Cysfs*3 variant was also genotyped using PCR and size fractionation. The
region around chr7:5997387 was ampliﬁed from genomic DNA from blood using
conventional PCR and size fractionated on 3730 DNA Analyser (Applied
Biosystems Inc.). The PMS2 p.Met1? variant was also genotyped using the
Centaurus (Nanogen) platform. All primer sequences are listed in Supplementary
Table 5. To assess the quality of the imputation, a set of imputed carriers and
non-carriers of the variants were genotyped using single marker assays, comparing
imputed genotypes to genotypes obtained by direct genotyping (see Supplementary
Table 1).
Whole-genome genetic analyses of the Icelandic population. WGS and
genotyping, imputation and association analysis used in the Icelandic population
were as described15. The whole genomes of 8,453 Icelanders were sequenced using
Illumina technology to a mean depth of at least 10 (median 32 ). SNPs and
indels were identiﬁed and their genotypes called for all samples simultaneously
using the Genome Analysis Toolkit (GATK version 2.2–13)31. Genotype calls were
improved by using information about haplotype sharing, taking advantage of the
fact that all the sequenced individuals had also been chip-typed and long range
phased. A total of 31.6 million SNPs and short indels that met stringent quality
criteria were identiﬁed in the 8,453 sequenced Icelanders. These variants were then
imputed into 150,656 Icelanders who had been genotyped with various Illumina
SNP chips and their genotypes phased using long-range phasing29–30. Genealogical
deduction of carrier status of 294,212 un-typed relatives of chip-typed individuals
further increased the sample size for association analysis and increased the power
to detect associations. Individuals who have any form of cancer and controls were
derived from the chip-typed individuals and un-typed relatives. Association testing
for case–control analysis was performed using logistic regression.
To account for inﬂation in test statistics due to cryptic relatedness and
stratiﬁcation, we applied the method of LD score regression32,33. With a set of
1.1M variants, we regressed the w2 statistics from our genome-wide association
study scan against LD score and used the intercept as a correction factor. The LD
scores were downloaded from an LD score database (see URL). For the traits
reported here, the estimated correction factors were 1.15 for CRC, 1.12 for colon
cancer, 1.04 for rectal cancer, 1.05 for endometrial cancer, 1.04 for ovarian cancer,
1.03 for brain cancer, 1.25 for breast cancer, 1.07 for bladder cancer, 1.02 for
esophageal cancer, 1.01 for gallbladder/bile duct cancer, 1.13 for gastric cancer,
1.02 for liver cancer, 1.00 for myelodysplastic syndrome, 1.09 for pancreatic cancer,
1.22 for prostate cancer, 1.01 for renal/ureteral cancer, 1.03 for testicular cancer.
Information on cancer in the study population. Individuals affected with all
forms of cancer were identiﬁed through the Icelandic Cancer Registry. The
Icelandic Cancer Registry contains all cancer diagnoses in Iceland from 1 January
1955. Over 90% of diagnoses are histologically conﬁrmed. The Icelandic Cancer
Registry contains records of 4,434 Icelandic CRC patients (52% males) diagnosed
from 1 January 1955 until 31 December 2013. Recruitment of cancer cases of all
types was initiated in 2001 and included all prevalent cases as well as newly
diagnosed cases from that time. Of the 1,685 CRC cases diagnosed from 1 January
2001–31 December 2013, 1,354 (80%) participated in our study. Patients are
recruited by trained nurses on behalf of the patients’ treating physicians, through
special recruitment clinics. Participants in the study sign an informed consent
form, donate a blood sample and answer a lifestyle questionnaire.
The median age at diagnosis for all consenting cases was 72 years, the same as
that for all CRC patients in the Icelandic Cancer Registry. In addition to the
chip-genotyped cases, we used information on 2,480 CRC cases without chip
information whose genotype probabilities were imputed using methods of familial
imputation15. The 262,425 controls (combined chip-typed and familially imputed)
used in this study consisted of individuals from other ongoing genome-wide
association studies at deCODE. No individual disease group is represented by more
than 10% of the total control group. Samples from other cancer cases used in the
cross-risk analysis come from other ongoing projects at deCODE Genetics. All
subjects were of European ancestry.
All sample identiﬁers were encrypted in accordance with the regulations of the
Icelandic Data Protection Authority. Approval for the study was granted by the
Icelandic National Bioethics Committee (ref. VSNb201410008/03.12) and the
Icelandic Data Protection Authority (ref. 2014101449).
The Icelandic genealogy. The Icelandic genealogical database contains 819,410
individuals back to 740 AD. Of the 471,284 Icelanders recorded to have been born
in the 20th century, 91.1% had a recorded father and 93.7% had a recorded mother
in the database. Similarly, of the 183,896 Icelanders recorded to have been born in
the 19th century, 97.5% had a recorded father and 97.8% had a recorded mother.
Haplotype analysis for the PMS2 frameshift mutation. Seven SNPs spanning
exons 5–9 in the PMS2 gene were analysed in patients carrying the PMS2
p.Pro246Cysfs*3 founder mutation and compared to the haplotype found in
carriers of this founder mutation in US, Swedish and British populations17.
These are described in Supplementary Table 3.
MLH1 translocation, karyotyping and FISH. To scan for structural variation, all
reads from the WGS data that align to the respective genes including 100 Kbp
ﬂanking regions to both sides of the genes were extracted. All reads that have a
mapping quality of 0 or an average PHRED-scaled base calling quality of 25 or
below were excluded. The remaining sets of reads were analysed for read pair
discordance: A read was considered be part of a discordant read pair if (1) its mate
is unaligned or aligns to a different chromosome or (2) the read and its mate align
in unexpected orientation to each other or (3) the distance between the alignment
positions of the read and its mate differ by more than three standard deviations
from the mean insert size of the sequencing library. The discordant pairs that
passed these ﬁlters were analysed manually for clusters where the reads align to
similar positions. Suspicious clusters were further examined for alternative align-
ment locations of the two read ends and discarded if the location in the reference
genome was repetitive. Further, clusters were discarded as common variants if
present in many whole-genome sequenced controls. The only cluster that passed all
ﬁlters indicates the translocation between chromosome 3 (MLH1) and chromo-
some 5 (ZCCHC10). The exact breakpoint positions and target-site events were
inferred from 36 soft-clipped reads from the two locations on chromosome 3 and 5
in the WGS data of one patient and conﬁrmed by 31 soft-clipped reads in a relative.
Metaphase chromosomes were harvested from PHA-stimulated
(phytohaemagglutinin) lymphocytes cultured in McCoy´s 5A medium with 20%
fetal calf serum applying standard methods. Chromosomes were G-banded and
karyotyped34. Whole chromosome FISH was performed with directly labelled
StarFISH paint probes (Gambio Ltd., Cambridge, UK) for chromosomes 3
(CY3-labelled) and 5 (ﬁtc-labelled) from Cambio, following their protocols.
Chromosomes were counterstained with DAPI (4,6-diamidino-2-phenylindole).
Image analysis was done using Leica CW4000 FISH software and Leica DMRA2
microscope with appropriate ﬁlters for FITC and Cy3.
Somatic tumour mutation and MSH2 methylation analysis. Three micrograms
of tumour DNA (1 ug in two biopsy cases) were used to perform ColoSeq tumour
next-generation sequencing in dMMR cases that remained unexplained after
germline mutation and MLH1-hm analysis and selected LS cases35. ColoSeq
tumour is a clinical diagnostic assay that detects single nucleotide, indel and
deletion/duplication mutations in MLH1, MSH2, MSH6, PMS2, and EPCAM as
well as the BRAF p.V600E mutation and phenotypic MSI. The assay uses paired-
end sequencing on the Illumina HiSeq 2500 instrument to sequence all exons,
introns, and ﬂanking sequences at 4300 average coverage. LOH was
determined by haplotype analysis of the variant allele fraction. Cases were
considered solved if: (1) Two pathogenic or likely pathogenic mutations were
identiﬁed (mutations identiﬁed as class 4 or 5 or predicted to result in protein
truncation); or (2) One pathogenic or likely pathogenic mutation was identiﬁed
with associated LOH. Cases were considered possibly solved if only one pathogenic
or likely pathogenic mutation was identiﬁed with possible LOH. Phenotypic MSI
was assessed with ColoSeq tumour next-generation sequencing data using mSINGS
(MSI by NGS)36.
One microgram tumour DNA was treated with sodium bisulphite using the EZ
Methylation Gold kit (Zymo Research, Irvine, California), according to the
manufacturer’s instructions. Approximately 100 ng bisulphite-converted template
was tested for the presence of methylation by two methods, quantitative CpG
pyrosequencing and real-time methylation-speciﬁc PCR (qMSP) and temperature
denaturation analysis, alongside the Universal Methylated Human DNA Standard
(fully methylated) and Human WGA Non-Methylated DNA (unmethylated)
control samples (Zymo Research, Irvine, California). CpG pyrosequencing was
conducted as previously described37 with some modiﬁcations. PCR ampliﬁcation
was performed with 1 mM of each primer 50-Biotin-TTTGGAAGTTGATTGGG
TGTGGT-30 and 50-CYACTTCTCCYACATACCCTAAAAAAAAC-30 and 3 mM
MgCl2 with cycling conditions of 95 C for 5min, followed by 45 cycles of 94 C for
30 s, annealing at 66 C for 30 s and extensions at 72 C for 30 s, then a ﬁnal
extension step at 72 C for 10min. PCR products were prepared for
pyrosequencing according to the standard protocol. Pyrosequencing was
performed using internal primer 50-CCACACCCACTAAACTATT-30 with
nucleotide dispensation order 50-CTA CGA CTC CTC ATC GAT CCA GAT CAG
ATC GAT ACA GAC ATC AGA TCA GAC AC-30 on the PyroMark Q96-ID
system (Qiagen). Methylation levels were measured using the PyroMark CpG
Methylation software. The methylation levels were quantiﬁed at six consecutive
CpG sites. Semi-quantitative methylation-speciﬁc PCR of the MSH2 promoter was
performed using primers 50-GTAGTAGTTAAAGTTATTAGCGTGCGCG-30 and
50-TCCTTCGACTACACCGCCATATCG-30 with cycling conditions of 95 C for
6min, followed by 42 cycles of 94 C for 30 s, annealing at 59 C for 30 s, and
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extension at 72 C for 30 s, followed by a melt curve from 65 C to 94 C at 0.5 C
increments for 5 s each. A MyoD control reaction for DNA input and
normalization of MSH2 methylation levels was included, as we have previously
described38. Real-time qMSP was performed on the CFX-96 Real-time System
(BioRad).
Data availability. The variants found in the MMR genes (pathogenic, likely
pathogenic and variants of unknown signiﬁcance) that support the ﬁndings of this
study have been deposited in InSiGHT (https://www.insight-group.org/variants/
databases/) with the accession codes (http://insight-database.org/variants/
0000004813 to http://insight-database.org/variants/0000004866). LD score data-
base (accessed 23 June 2015) ftp://atguftp.mgh.harvard.edu/ brendan/1k_eur_-
r2_hm3snps_se_weights.RDS. All other remaining data are available within the
Article and Supplementary Files, or available from the authors upon request.
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